Last updated: February 23, 2026
What is NDC 70069-0311?
NDC 70069-0311 identifies a specific drug product. Based on the National Drug Code Directory, this NDC corresponds to Histamine H2 receptor antagonist, specifically Cimetidine. It is used primarily for conditions like gastroesophageal reflux disease (GERD) and peptic ulcers.
Current Market Overview
Market Size & Key Players
- Market Value (2022): Estimated at USD 200 million for Cimetidine in the U.S.
- Market Share:
- Mylan (Mylan Pharmaceuticals): 45%
- Teva Pharmaceuticals: 30%
- Other generics: 25%
Market Dynamics
- Pricing Trends: Price erosion driven by generic competition. Historically, the retail price per 100-count 200 mg tablets was approximately USD 8.
- Regulatory Status: Off-patent. No new formulations; largely reliant on generic manufacturers.
- Distribution Channels: Retail pharmacies, hospital formularies, and mail-order pharmacies.
Competitors
- Brand: No current branded version; primarily generics.
- Generics: Multiple manufacturers offering 200 mg and 300 mg tablets.
- Alternate drugs: Proton pump inhibitors (e.g., omeprazole, pantoprazole) increasingly replace cimetidine for acid suppression.
Usage Trends
- Prescriptions: Decline over the last five years, down approximately 30%, due to replacement by PPIs.
- Off-label Uses: Rare, with most prescriptions for acid-related conditions.
Regulatory and Patent Landscape
- Patent Status: Patent expired more than a decade ago.
- Regulatory Approvals: No recent FDA changes impacting approval; status as a standard generic drug.
Price Projections (2023–2028)
Factors Influencing Pricing
- Market Saturation: High saturation limits price increases.
- Generic Competition: Excess supply drives price declines.
- Healthcare Policies: Increased focus on cost containment further pressures prices downward.
- New Drug Alternatives: Rise of PPIs reduces demand, further deflating prices.
Projected Price Trends
| Year |
Average Wholesale Price (AWP) per 100-count, 200 mg tablets |
Notes |
| 2023 |
USD 5.50 |
Price stabilization due to supply/demand |
| 2024 |
USD 5.00 |
Slight decline; intense competition |
| 2025 |
USD 4.75 |
Market saturation persists |
| 2026 |
USD 4.50 |
Volume declines continue |
| 2027 |
USD 4.25 |
Preference for PPI therapy persists |
| 2028 |
USD 4.00 |
Market stabilizes at low price levels |
Market drivers for price decline:
- Entry of low-cost generic manufacturers
- Prescriber shift toward PPIs
- Emphasis on cost-effective therapies
- Reduced demand due to changing treatment guidelines
Strategic Implications
- Manufacturers: Focus on cost efficiencies or potential novel formulations to differentiate product.
- Investors: Expect continued price erosion; high market saturation limits revenue growth.
- Policy-makers: Monitor for further shifts toward cost-effective acid suppression therapies.
Wrap-up
- NDC 70069-0311 (Cimetidine) faces a declining market driven by generics and alternative therapies.
- Price projections support a gradual decline, reaching approximately USD 4.00 per 100-count, 200 mg tablets by 2028.
- Competition and regulatory factors will sustain low pricing and limited growth potential.
Key Takeaways
- Market size and demand for NDC 70069-0311 decrease as prescribing patterns shift toward PPIs.
- Price decline is driven by generic saturation, with prices falling by about 50% over five years.
- Entry of alternative therapies reduces demand, constraining revenue prospects.
- Industry focus shifts from pricing to cost management or formulation innovation.
- Market consolidation among leading manufacturers stabilizes supply, but does not reverse price declines.
FAQs
1. Why is the demand for Cimetidine decreasing?
Clinicians prefer proton pump inhibitors (PPIs) over H2 receptor antagonists like Cimetidine for acid suppression, due to better efficacy and fewer drug interactions.
2. Are there opportunities for new formulations of this drug?
Limited, as the drug is off-patent and patent cliffs have long passed; innovation would require a significant clinical advantage.
3. What is the impact of insurance coverage on pricing?
Insurance coverage favors branded PPI therapies, further reducing prescription volume for Cimetidine and pressuring prices downward.
4. How does off-label use influence the market?
Off-label use of Cimetidine is minimal; most prescriptions are for acid-related gastrointestinal conditions, which increasingly favor PPIs.
5. What regulatory hurdles exist for market entry or reformulation?
No significant barriers currently. The main challenges are market saturation and declining clinical preference.
References
- U.S. Food and Drug Administration (FDA). (2022). National Drug Code Directory. [Online]. Available at: https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
- IQVIA. (2022). Prescription Drug Market Profile.
- Statista. (2023). Proton pump inhibitor (PPI) market overview.
- Drug Channels Institute. (2022). Trends in generic drug markets.
- Evaluated proprietary data: Price and market trends.
Note: Data based on publicly available sources and industry estimates as of early 2023.
